Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM24SOL)

Drug Name

MLN1202 Drug Info

Synonyms

UNNCHYARSNZOPF-UHFFFAOYSA-L; RFI-641; UNII-FR2W015BG1; FR2W015BG1; WAY-154641; CHEMBL425633; SCHEMBL20741446; RF-1461

Indication

Disease Entry	ICD 11	Status	REF
Metastatic cancer	2D50-2E2Z	Phase 2	[1]
Multiple sclerosis	8A40	Phase 2	[1]
Respiratory syncytial virus infection	1C80	Terminated	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Antagonist	[3]
Measles virus Fusion glycoprotein (MeV F)	TTUPB12	FUS_MEASC	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Metastatic cancer

ICD Disease Classification

2D50-2E2Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
C-C chemokine receptor type 2 (CCR2)	DTT	CCR2	5.26E-01	4.75E-03	0.03

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
2	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
3	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.